

Andreas Weihofen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/605759/publications.pdf>

Version: 2024-02-01

23
papers

3,341
citations

394286

19
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

5794
citing authors

#	ARTICLE	IF	CITATIONS
1	Dopamine covalently modifies and functionally inactivates parkin. <i>Nature Medicine</i> , 2005, 11, 1214-1221.	15.2	658
2	Identification of Signal Peptide Peptidase, a Presenilin-Type Aspartic Protease. <i>Science</i> , 2002, 296, 2215-2218.	6.0	521
3	The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. <i>Journal of Neurochemistry</i> , 2011, 117, 856-867.	2.1	313
4	Pink1 Forms a Multiprotein Complex with Miro and Milton, Linking Pink1 Function to Mitochondrial Trafficking. <i>Biochemistry</i> , 2009, 48, 2045-2052.	1.2	277
5	Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. <i>Trends in Cell Biology</i> , 2003, 13, 71-78.	3.6	197
6	Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes. <i>Journal of Immunology</i> , 2001, 167, 6441-6446.	0.4	167
7	LRRK2 Antisense Oligonucleotides Ameliorate α -Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 508-519.	2.3	167
8	Pink1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. <i>Human Molecular Genetics</i> , 2008, 17, 602-616.	1.4	138
9	Randomized phase I clinical trial of anti- α -synuclein antibody BIIB054. <i>Movement Disorders</i> , 2019, 34, 1154-1163.	2.2	128
10	Development of an aggregate-selective, human-derived α -synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. <i>Neurobiology of Disease</i> , 2019, 124, 276-288.	2.1	125
11	Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with β -Secretase Inhibitors. <i>Journal of Biological Chemistry</i> , 2003, 278, 16528-16533.	1.6	114
12	Release of Signal Peptide Fragments into the Cytosol Requires Cleavage in the Transmembrane Region by a Protease Activity That Is Specifically Blocked by a Novel Cysteine Protease Inhibitor. <i>Journal of Biological Chemistry</i> , 2000, 275, 30951-30956.	1.6	111
13	Consensus Analysis of Signal Peptide Peptidase and Homologous Human Aspartic Proteases Reveals Opposite Topology of Catalytic Domains Compared with Presenilins. <i>Journal of Biological Chemistry</i> , 2004, 279, 50790-50798.	1.6	90
14	Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. <i>Human Molecular Genetics</i> , 2009, 18, 4317-4328.	1.4	77
15	α -Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. <i>JCI Insight</i> , 2021, 6, .	2.3	60
16	Post-transcriptional Regulation of the <i>Streptomyces coelicolor</i> Stress Responsive Sigma Factor, SigH, Involves Translational Control, Proteolytic Processing, and an Anti-sigma Factor Homolog. <i>Journal of Molecular Biology</i> , 2003, 325, 637-649.	2.0	42
17	A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α -Synuclein Mice. <i>Annals of Neurology</i> , 2021, 89, 74-90.	2.8	40
18	The Parkinson's disease-associated gene ITPKB protects against α -synuclein aggregation by regulating ER-to-mitochondria calcium release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	35

#	ARTICLE	IF	CITATIONS
19	Neurodegeneration and neuroinflammation are linked, but independent of alpha-synuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease. <i>Glia</i> , 2022, 70, 935-960.	2.5	30
20	Wild-type GBA1 increases the α -synuclein tetramer/monomer ratio, reduces lipid-rich aggregates, and attenuates motor and cognitive deficits in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	21
21	Discovery of small-molecule positive allosteric modulators of Parkin E3 ligase. <i>IScience</i> , 2022, 25, 103650.	1.9	11
22	SCD Inhibition Protects from α -Synuclein-Induced Neurotoxicity But Is Toxic to Early Neuron Cultures. <i>ENeuro</i> , 2021, 8, ENEURO.0166-21.2021.	0.9	8
23	Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models. <i>Neuroscience Letters</i> , 2022, 772, 136491.	1.0	3